A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Cervical Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 3
- Patients
- 686 (planned)
- Started
- Jul 24, 2024
- Main results expected
- Jun 15, 2028
- Fully finished
- Jun 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-in
Measured over: Up to approximately 46 months
Number of Participants Experiencing One or More Adverse Events (AEs) in Sacituzumab Tirumotecan Run-in
Measured over: Up to approximately 46 months
Number of Participants Discontinuing Study Treatment Due to an AE in Sacituzumab Tirumotecan Run-in
Measured over: Up to approximately 46 months
Overall Survival (OS) in Phase 3 Portion
Measured over: Up to approximately 35 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["eligibilityModule","statusModule"]}
Trial ID NCT06459180 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC